

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

**Date of Report (Date of earliest event reported) December 6, 2017**

---

**XOMA CORPORATION**  
(Exact name of registrant as specified in its charter)

---

**000-14710**  
(Commission  
File Number)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**52-2154066**  
(IRS Employer  
Identification No.)

**2200 Powell Street, Suite 310, Emeryville, California**  
(Address of principal executive offices)

**94608**  
(Zip Code)

**Registrant's telephone number, including area code (510) 204-7200**

(Former name or former address, if changed since last report.)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

---

**Item 1.01. Entry into a Material Definitive Agreement**

On December 6, 2017, XOMA Corporation (the “Company,” “XOMA” or “we”), through its wholly-owned subsidiary, XOMA (US) LLC, entered into a license agreement (“License Agreement”) with AntriaBio, Inc. (“AntriaBio”) pursuant to which we granted an exclusive global license to AntriaBio to develop and commercialize XOMA 358 (X358) for all indications. The Company and AntriaBio also entered into a common stock purchase agreement (the “Purchase Agreement” and, together with the License Agreement, the “Transaction Documents”).

Under the terms of the License Agreement, AntriaBio is responsible for all development, regulatory, manufacturing and commercialization activities associated with X358 and is required to make certain clinical, regulatory and annual net sales milestone payments to us of up to \$222 million in the aggregate based on the achievement of pre-specified criteria. AntriaBio is also obligated to pay XOMA royalties ranging from the high single digits to the mid-teens based upon annual net sales of X358. Finally, under the terms of the License Agreement, AntriaBio is required to pay XOMA a low single digit royalty on sales of AntriaBio’s other products from its current programs. AntriaBio is obligated to take customary steps to advance X358, including using diligent efforts to commence the next clinical study for X358 by a certain deadline and to meet certain spending requirements on an annual basis for the program until a marketing approval application for X358 is accepted by the FDA.

AntriaBio’s obligation to pay milestones will continue for so long as AntriaBio is developing or selling products under the License Agreement, subject to the maximum milestone payment amounts set forth above. AntriaBio’s obligation to pay royalties with respect to a particular X358 product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or twelve years from the date of the first commercial sale of the product in that country. AntriaBio’s obligation to pay royalties with respect to a particular AntriaBio product and country will continue for the longer of twelve years from the date of the first commercial sale of the product in that country or for so long as AntriaBio or its licensee is selling such product in such country, provided that such royalty will terminate upon the termination of the licensee’s obligation to make payments to AntriaBio based on sales of such product in such country.

The License Agreement contains customary termination rights relating to material breach by either party. AntriaBio also has a unilateral right to terminate the License Agreement in its entirety on ninety days’ notice at any time. XOMA has the right to terminate the License Agreement if AntriaBio challenges the licensed patents.

Pursuant to the Transaction Documents, the AntriaBio is also required to pay us \$6 million in cash and to issue us \$12 million worth of its common stock related to its financing activities. Further, in the event that AntriaBio does not conduct a financing that raises at least \$20 million in aggregate gross proceeds (“Qualified Financing”) by March 31, 2019, then it shall issue to XOMA an additional number of shares of its common stock equal to \$7 million divided by the weighted average of the closing bid and asked prices or the average closing prices of AntriaBio’s common stock on the ten day trading period prior to March 31, 2019. Finally, in the event that AntriaBio is unable to complete a Qualified Financing by March 31, 2020, it will be obliged to pay XOMA \$15 million in order to maintain the license.

The descriptions of the License Agreement and the Purchase Agreement contained herein do not purport to be complete and are qualified in their entirety by reference to such agreements, together with the exhibits thereto, copies of which will be filed as exhibits to XOMA’s Annual Report on Form 10-K for the period ending December 31, 2017. Certain terms of the License Agreement have been omitted from this Form 8-K and will be omitted from the version to be filed as an exhibit to the Form 10-K pursuant to a Confidential Treatment Request that the Company plans to submit to the Securities and Exchange Commission at the time of the filing of the Form 10-K.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

XOMA CORPORATION

/s/ Thomas Burns

Thomas Burns

Senior Vice President, Finance and Chief Financial Officer

Date: December 11, 2017